InMed Pharmaceuticals

Investor Insight InMed is a pharmaceutical drug development company advancing proprietary small-molecule drugs in Alzheimer’s and ophthalmology, backed by a revenue-generating manufacturing subsidiary. The company is an undervalued opportunity with cash exceeding market capitalization and multiple upcoming catalysts. Overview InMed Pharmaceuticals (NASDAQ:INM) is a biopharmaceutical company with a differentiated business model: advancing innovative therapeutic programs…

Read More

Is the AI Arms Race Bolstering Demand for Gold?

The gold price has been trading at record highs above US$4,000 per ounce since October. As top tech companies like NVIDIA (NASDAQ:NVDA), Microsoft (NASDAQ:MSFT) and Alphabet (NASDAQ:GOOGL) battle for AI supremacy, investors are wondering if this arms race is boosting the rush to gold. Gold is an essential material in sophisticated computer infrastructure, sparking headlines…

Read More

Silver Stocks: 5 Biggest Companies in 2025

Silver mining companies are being supported by a silver price bull run in 2025. After climbing through 2025, silver broke its all-time high set in 1980 this October, reaching a new high of US$54.47 per ounce on October 17. The factors driving the metal’s rise remain, most notably tightening supply and demand fundamentals driven by…

Read More

Living Plants Offer New Path to Rare Earths Supply, Study Shows

Researchers have documented the first known recovery of naturally formed nanoscale monazite from a living plant, potentially opening up new paths to recover in-demand rare earth materials. The study, published this month in Environmental Science & Technology, identifies nanoscale monazite crystals inside Blechnum orientale, an evergreen fern known to accumulate rare earths at unusually high…

Read More
Back To Top